Focus on upcoming CRB-701 data at ASCO 2026 and CANYON-1 topline results later this summer — these are the primary value catalysts. The slight EPS beat and FDA alignment provide near-term support, but sustained cash burn and no revenue require continued milestone execution.
Price Chart
Executive Summary
Corbus Pharmaceuticals reported Q1 2026 net loss of $23.0M ($1.23/share), slightly beating the $1.26 consensus estimate. Key clinical progress includes FDA alignment on CRB-701 registration path and completed enrollment in the CANYON-1 obesity study, with topline data expected summer 2026. Increased operating expenses drove wider losses, but cash runway extends into 2028.
Key Financial Metrics
Key Facts
- Q1 2026 net loss: $23.0M vs $17.0M in Q1 2025
- EPS: $(1.23) vs consensus $(1.26) (beat by 2.4%)
- Cash, cash equivalents and investments: $138.2M as of March 31, 2026
- FDA alignment reached on registration path for CRB-701 in HNSCC and cervical cancer
- CANYON-1 Phase 1b obesity study (n=240) enrollment completed; topline data expected summer 2026
- Weighted average shares outstanding increased to 18.7M from 12.2M year-over-year
Financial Impact
Widening net loss of $23M (+35% YoY) for a pre-revenue biotech; cash burn rate increased due to clinical development.
Risk Factors
- Clinical trial failure or disappointing data for CRB-701 or CRB-913
- Cash burn may require further dilution if milestones are delayed
- Competition in Nectin-4 ADC (e.g., Padcev) and obesity (GLP-1s) markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218250 |
| Document: crbp-20260512.htm | 0001193125-26-218250 |
| Document: 0001193125-26-218250-index-headers.html | 0001193125-26-218250 |
| Document: 0001193125-26-218250-index.html | 0001193125-26-218250 |
| Document: 0001193125-26-218250.txt | 0001193125-26-218250 |
| 8-K Data (Synthetic) | 0001193125-26-218250 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $4.15 (−4.16%) |
Sep 30, 2026 26d ago | SC 13G | $6.34 | awaiting T+60 | — | $4.15 (−34.54%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $4.15 (−47.30%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $4.15 (−58.83%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $4.15 (−56.36%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $4.15 (−47.53%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $4.15 (−63.94%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $4.15 (−65.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers